Addressing Challenges in Neuromodulation

Neuromodulation, acknowledged for its efficacy in treating chronic, intractable neuropathic pain, is a focal point of research at SPRC. The ongoing research delves into refining methods of programming, exploring clinical indications, targeting diverse populations, and overcoming the challenge of decreasing device size while maintaining safety and efficacy. Despite the technological advancements, a notable concern voiced by patients revolves around the difficulties and burdens associated with recharging their devices, potentially leading to suboptimal usage and diminished patient satisfaction. SPMC’s visionary aim is to develop the world’s first implantable battery device capable of harvesting and storing energy generated by the body’s own systems to power spinal cord stimulators. This ambitious initiative seeks to eradicate the clinical barriers to neuromodulation, ultimately improving the patient experience and enhancing outcomes in chronic pain management.

SPRC Clinical Trials: Catalysts for Progress

SPRC’s commitment to pushing the boundaries of pain medicine is exemplified through its active participation in numerous national and international clinical trials. Our steadfast adherence to rigorous ethical standards, encompassing human ethics and hospital governance approvals, underscores our dedication to upholding scientific integrity.
A milestone is the successful completion of the SALIENT trial, a 9-month investigation into the efficacy of SX600, a dexamethasone derivative administered via lumbosacral transforaminal epidural injection for radicular pain. Notably, the Sydney Pain Research Centre enrolled the second-highest number of participants globally. Additionally, our involvement in groundbreaking trials such as those conducted with Nalu Medical and Medtronic further underscores our comprehensive and patient-centric approach to pain management. The Nalu Medical trial focused on evaluating the efficacy and safety of the Nalu Neurostimulation System, renowned for its compact size and potential to mitigate discomfort at the surgical site while providing effective pain relief. Furthermore, as the inaugural site for the NeuroSense study, we have pioneered the evaluation of long-term patient experience with the Medtronic Closed-Loop SCS System. This cutting-edge technology, spearheaded by Dr. Mohabbati, introduces specialized features to prevent overstimulation, enhance patient satisfaction, and potentially reduce overall pain intensity.

Collaboration with UNSW: Leveraging Collective Expertise

In line with its commitment to collaborative research, SPMC actively collaborates with the University of New South Wales (UNSW) as part of the ARC Research Hub for Connected Sensors for Health. This collaboration harnesses interdisciplinary expertise to address challenges in biophysical and biochemical sensors, energy solutions, and data analytics for enhanced health outcomes. The integration of UNSW’s team into the hub adds depth and breadth to the research initiatives, fostering an environment where collective knowledge propels the boundaries of healthcare innovation.

Looking Ahead: A Vision for Transformative Healthcare